EdgarLookup

SELLAS Life Sciences Group, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that SELLAS Life Sciences Group, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2023 Sep 30, 2023 $0 Nov 9, 2023
Q2 2023 Jun 30, 2023 $0 Aug 10, 2023
Q1 2023 Mar 31, 2023 $0 May 11, 2023
Q3 2023 Sep 30, 2022 $0 Nov 9, 2023
Q2 2023 Jun 30, 2022 $0 Aug 10, 2023
Q1 2023 Mar 31, 2022 $1.00M May 11, 2023
Q3 2022 Sep 30, 2021 $0 Nov 14, 2022
Q2 2022 Jun 30, 2021 $1.90M Aug 11, 2022
Q1 2022 Mar 31, 2021 $5.70M May 12, 2022
Q3 2021 Sep 30, 2020 $0 Nov 12, 2021
Q2 2021 Jun 30, 2020 $0 Aug 12, 2021
Q1 2021 Mar 31, 2020 $0 May 13, 2021

Revenue (Net Sales) — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2015 Jun 30, 2015 $3.38M Aug 6, 2015
Q1 2015 Mar 31, 2015 $2.75M May 7, 2015
Q3 2014 Sep 30, 2014 $1.62M Nov 5, 2014
Q2 2015 Jun 30, 2014 $2.33M Aug 6, 2015
Q1 2015 Mar 31, 2014 $2.17M May 7, 2015
Q3 2014 Sep 30, 2013 $1.17M Nov 5, 2014
Q2 2014 Jun 30, 2013 $0 Aug 11, 2014
Q1 2014 Mar 31, 2013 $0 May 6, 2014
Q3 2013 Sep 30, 2012 $0 Nov 7, 2013

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($6.79M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($6.60M) Aug 12, 2025
Q1 2025 Mar 31, 2025 ($5.81M) May 13, 2025
Q3 2025 Sep 30, 2024 ($7.11M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($7.47M) Aug 12, 2025
Q1 2025 Mar 31, 2024 ($9.57M) May 13, 2025
Q3 2024 Sep 30, 2023 ($9.27M) Nov 13, 2024
Q2 2024 Jun 30, 2023 ($8.84M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($11.10M) May 14, 2024
Q3 2023 Sep 30, 2022 ($7.02M) Nov 9, 2023
Q2 2023 Jun 30, 2022 ($8.41M) Aug 10, 2023
Q1 2023 Mar 31, 2022 ($16.74M) May 11, 2023
Q3 2022 Sep 30, 2021 ($7.09M) Nov 14, 2022
Q2 2022 Jun 30, 2021 ($4.61M) Aug 11, 2022
Q1 2022 Mar 31, 2021 ($2.40M) May 12, 2022
Q3 2021 Sep 30, 2020 ($4.47M) Nov 12, 2021
Q2 2021 Jun 30, 2020 ($4.43M) Aug 12, 2021
Q1 2021 Mar 31, 2020 ($4.14M) May 13, 2021
Q3 2020 Sep 30, 2019 ($4.20M) Nov 13, 2020
Q2 2020 Jun 30, 2019 ($3.13M) Aug 13, 2020

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($7.08M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($6.87M) Aug 12, 2025
Q1 2025 Mar 31, 2025 ($6.06M) May 13, 2025
Q3 2025 Sep 30, 2024 ($7.33M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($7.62M) Aug 12, 2025
Q1 2025 Mar 31, 2024 ($9.65M) May 13, 2025
Q3 2024 Sep 30, 2023 ($9.36M) Nov 13, 2024
Q2 2024 Jun 30, 2023 ($9.05M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($11.28M) May 14, 2024
Q3 2023 Sep 30, 2022 ($7.15M) Nov 9, 2023
Q2 2023 Jun 30, 2022 ($8.62M) Aug 10, 2023
Q1 2023 Mar 31, 2022 ($16.74M) May 11, 2023
Q3 2022 Sep 30, 2021 ($6.98M) Nov 14, 2022
Q2 2022 Jun 30, 2021 ($4.45M) Aug 11, 2022
Q1 2022 Mar 31, 2021 ($2.25M) May 12, 2022
Q3 2021 Sep 30, 2020 ($4.49M) Nov 12, 2021
Q2 2021 Jun 30, 2020 ($4.27M) Aug 12, 2021
Q1 2021 Mar 31, 2020 ($4.06M) May 13, 2021
Q3 2017 Sep 30, 2017 ($4.46M) Nov 9, 2017
Q2 2017 Jun 30, 2017 ($4.91M) Aug 14, 2017